Constraints Flashcards
What is the usual CW constraint for peripheral lung SBRT lesions?
For 3 fx lung SBRT
- V30 < 30 cc
Caveats:
- May not always be possible for peripheral lesions
- Do not compromise target coverage
- ASTRO guidelines explicitly forbid from trimming PTV to meet this CW constraint
- CW tox (pain, etc) is usually amenable to conservative management
What is the threshold for CW dose before Gr ≥ 2 CW tox is observed in lung SBRT pts>
- V30 Gy > 70 cc
– V30Gy < 70 cc may be a more practical constraint for peripheral lung SBRT pts
What are the usual OAR constraints for lung SBRT?
What are the SRS Dmax constraints for the Optic nerve (ON)?
SRS constraints for ON:
- Dmax < 8 Gy
– Rare (~0%) risk of optic neuropathy
- Dmax < 12 Gy
– <10% risk of optic neuropathy
What are the NCCN dose constraints for the lungs for pts receiving CFRT for esophageal or gastric cancers?
Lung constraints for esophageal cancer CFRT?
- V40Gy ≤ 10%
- V30Gy ≤ 15%
- V20Gy ≤ 20%
- V10Gy ≤ 40%
- V5Gy ≤ 50%
- Dmean < 20 Gy
What are acceptable lung constraints for centrally located lesions undergoing 5 fx SBRT?
- V20Gy < 10% (minor deviation < 15%)
- D1500cc max 12.5 Gy
- D1000cc max 13.5 Gy
What are the NCCN dose constraints for the spine for pts receiving CFRT for esophageal or gastric cancers?
Spine constraints for esophageal cancer CFRT:
- Dmax ≤ 45 Gy
What are the NCCN dose constraints for the bowel for pts receiving CFRT for esophageal or gastric cancers?
Bowel constraints for esophageal cancer CFRT:
- Dmax < 54 Gy
- V 45Gy < 195 cc
What are the NCCN heart dose constraints for pts receiving CFRT for esophageal or gastric cancers?
Heart constraints for esophageal cancer CFRT:
- V30Gy ≤ 30 % (20% preferred)
- Dmean < 30 Gy (26 Gy preferred)
What are the NCCN stomach dose constraints for pts receiving CFRT for esophageal or gastric cancers?
Stomach constraints for esophageal cancer CFRT:
- Dmean < 45 Gy
- Dmax < 54 Gy
What are the NCCN liver dose constraints for pts receiving CFRT for esophageal or gastric cancers?
Liver constraints for esophageal cancer CFRT:
- V30Gy ≤ 33%
- Dmean < 25 Gy
What are the NCCN kidney dose constraints for pts receiving CFRT for esophageal or gastric cancers?
Kidney constraints for esophageal cancer CFRT:
- V20Gy ≤ 33%
- Dmean <18 Gy
– Corresponds to a <5% risk of relevant kidney dysfunction
For liver SBRT, what are the allowed Dmean for the liver?
Liver constraints for Lung SBRT:
- 50 Gy in 5 fx:
– Dmean < 13 Gy
- 27.5 Gy in 5 fx:
– Dmean < 17 Gy
What is the % risk of developing symptomatic pneumonitis when using the lung dose constraint (V20Gy < 30%)?
< 20%
What are the dose constraints for the cochlea for CFRT?
- Dmean ≤ 45 Gy (≤ 35, preferred)
– < 30% risk of sensory-neural hearing loss - Dmean < 32 Gy
– < 20% risk of grade 2+ tinnitus
What are the dose constraints for the cochlea for SRS?
Dmax < 9 Gy
Dmean < 3 Gy
What are the QUANTAC rectal dose constraints to keep grade ≥2 late rectal toxicity < 15% and grade ≥3 late rectal toxicity < 10%?
Rectal Dose Constraints:
- V50Gy < 50%
- V60Gy < 35%
- V65Gy < 25% (65+25=90)
- V70Gy < 20% (70+20=90)
- V75Gy < 15% (75+15=90)
Rule of 90s for the three highest constraints!
Also, related to bladder constraints:
- V75 < 25%; Subtract 10% for rectum (V75 < 15%)
- V70 < 35%; Subtract 15% for rectum (V70 < 20%)
- V65 < 50%; Subtract 25% for rectum (V65 < 25%)
What are the QUANTAC bladder dose constraints for CFRT?
Bladder Dose Constraints:
- V65Gy < 50%
- V70Gy < 35%
- V75Gy < 25%
- V85Gy < 15%
Memory Hook:
- Bladder:
– V75 < 25%; Subtract 10% for rectum (V75 < 15%)
– V70 < 35%; Subtract 15% for rectum (V70 < 20%)
– V65 < 50%; Subtract 25% for rectum (V65 < 25%)
What is the SRS brainstem constraint to keep the risk of necrosis or cranial neuropathy < 5%?
SRS Brainstem constraint
- Dmax < 12.5 Gy
What are the QUANTAC pharyngeal constrictor dose constraint to keep the risk of dysphagia or symptomatic aspiration < 20%?
Dmean < 50 Gy
What is the QUANTAC penile bulb dose constraint to keep the risk of ED < 35%?
- Dmean to 95% < 50 Gy
- D90 < 50 Gy
- D70 < 70 Gy
Which sites in an adult human body harbor bone marrow and in what proportions?
What were the trachea/bronchus constraints on the RTOG 0813 dose-escalation trial for centrally located NSCLC?
- V18 Gy < 4 cc
- Dmax < 105% of Rx
- decreases the risk of stenosis and fistula formation